Genentech Inc.

Private Subsidiary, Headquarters Location
1 DNA Way, South San Francisco, CA 94080-4918, United States
(800)626-3553, (650)225-1000, http://www.gene.com

Primary SIC: Pharmaceutical Preparations, Primary NAICS: Pharmaceutical Preparation Manufacturing
Description: San Francisco-based Genentech Inc. was founded 30 years ago, in 1976, by the late venture capitalist Robert A. Swanson and the biochemist Dr. Herbert W. Boyer. The company went public in 1980 and had one of the highest stock run-ups in history. Genentech uses human genetic information to discover, develop, manufacture and commercialize pharmaceutical products to treat patients with serious or life-threatening medical conditions in the United States. Genentech currently has multiple products on the market for serious or life-threatening medical conditions, including: Avastin, Heceptin, Rituxan and Taceva in the area of bio-oncology; Raptiva and Xolair in the area of immunology; and Activase, CathfloActivase, Nutropin, Nutropin AQ, Pulmozyme and TNKase. In March 2009, Genentech was acquired by Roche and became a wholly-owned member of the Roche Group. As of March 26, 2009, the company's common stock is no longer being traded on the New York Stock Exchange. More

Manufacturing: Biotechnology company using human genetic information (DNA) to discover, develop, manufacture and market human pharmaceuticals. Services: Genetic research relating to pharmaceutical development.